Introduction
A crucial role of vascular endothelial growth factor (VEGF) in angiogenesis and tumor progression in both solid tumors and hematological malignancies has been well established (Ferrara, 2002; Podar and Anderson, 2004; Xie et al., 2004) . Inhibiting VEGF and/or VEGF receptor signaling -alone or in combination with other treatments -has shown promise for tumor antiangiogenesis therapy in both animal models and cancer patients (Benjamin et al., 1999; Klement et al., 2000; Inoue et al., 2002; Huss et al., 2003) . However, a large array of oncoproteins overactive in cancer cells act as VEGF inducers, creating a challenge for blocking tumor VEGF production. Phosphatidylinosital-3-kinase (PI3K) and Akt signaling plays an important role in the regulation of VEGF expression (Laughner et al., 2001; Semenza, 2003) . Both PI3K and Akt are frequently activated in a wide range of human cancers by either gain-of-function of oncogenic proteins or by loss-of-function of negative regulator, phosphatase and tensin homologue deleted on chromosome 10 (PTEN) (Vivanco and Sawyers, 2002; Semenza, 2003) . The PI3K/Akt signaling pathway upregulates expression of VEGF in both tumor and endothelial cells, and hypoxia inducible factor-1 (HIF-1) mediates PI3K/Akt-induced VEGF expression (Jiang et al., 2000; Laughner et al., 2001; Semenza, 2003) . In addition to controlling angiogenesis, HIF-1 regulates metabolic adaptation to hypoxia and other critical aspects of tumor progression (Semenza, 2003) . HIF-1 consists of two subunits: an inducible HIF-1a subunit and a constitutively expressed HIF-1b subunit (Forsythe et al., 1996; Semenza, 2003; Tan et al., 2004) . In solid tumors, HIF-1a is frequently upregulated by intratumoral hypoxia through loss of von Hippel-Lindau (VHL) or p53 function (Semenza, 2003) . Deregulation of growth signaling pathways in both solid and hematological malignancies is common, and upregulation of HIF-1 by abnormal growth signaling has been shown to be at the protein synthesis level and mediated by PI3K/Akt pathway. It has been demonstrated that inhibition of mTOR by rapamycin abrogates HIF-1a induction by growth signaling pathways (Semenza, 2003) .
Recent studies have also identified Stat3 as a direct transcription activator of the VEGF gene (Niu et al., 2002b; Wei et al., 2003a) . Activation of Stat3 leads to tumor angiogenesis in vivo (Niu et al., 2002b) and blocking Stat3 signaling in tumors can reduce tumor angiogenesis (Wei et al., 2003a, b) . A role of Stat3 in upregulating VEGF expression in diverse human cancers has also been demonstrated (Repovic et al., 2003; Wei et al., 2003a, b) . Importantly, constitutive activation of Stat3 occurs at 50-90% frequency in a broad range of human cancers (Grandis et al., 1998; Catlett-Falcone et al., 1999; Darnell, 2002; Niu et al., 2002a; Yu and Jove, 2004) , suggesting that Stat3 activity contributes significantly to tumor VEGF overproduction.
The Jak/STAT and PI3K/Akt are two parallel pathways mediating functions of many receptor and nonreceptor tyrosine kinases, including EGFR, Her-2 and c-Src (Liu et al., 1998; Laughner et al., 2001; Niu et al., 2002b; Rane and Reddy, 2002; Vivanco and Sawyers, 2002; Wei et al., 2003b; Yu and Jove, 2004) . IL-6 receptor (IL-6R), which is frequently activated in a wide range of cancers (Hideshima et al., 2004) , also signals through both Jak/STAT and PI3K/Akt pathways (Catlett-Falcone et al., 1999; Hideshima et al., 2001 ). Overexpression and/or persistent activation of EGFR/Her-2, Src and IL-6R are known to promote tumor growth/survival and to induce VEGF expression and angiogenesis (Porter and Vaillancourt, 1998; Dankbar et al., 2000; Laughner et al., 2001; Darnell, 2002; Niu et al., 2002a, b; Vivanco and Sawyers, 2002; Semenza, 2003; Wei et al., 2003b; Yu and Jove, 2004) . As IL-6 activates the PI3K/Akt pathway (Hideshima et al., 2001) , engagement of IL-6R is predicted to affect HIF-1a expression. Interestingly, it has been shown that blocking Stat3, but not PI3K activity, inhibits VEGF expression in tumor cells with constitutive IL-6R signaling (Wei et al., 2003b) , suggesting that Stat3 continues to activate VEGF expression in the absence of PI3K/Akt signaling.
In this study, we show that Stat3 is obligatory for both basal and growth signal-induced HIF-1a expression. Moreover, VEGF upregulation by multiple oncogenic proteins/growth pathways is abrogated in the absence of Stat3 signaling. We further demonstrate that Stat3 is required and sufficient for Akt1 expression. Our results also show that targeting Stat3 by a smallmolecule drug inhibits human melanoma growth and angiogenesis in a xenograft model. Furthermore, tumor angiogenesis induced by IL-6, which simultaneously activates Jak/STAT and PI3K/Akt, is attenuated in Stat3 knockdown tumor cells in vivo. These results demonstrate that Stat3 is a key regulator of the VEGF gene; in addition to being a direct activator of the VEGF promoter, Stat3 is required for PI3K-Aktmediated HIF-1 expression, a key regulator of the VEGF gene. As such, strategically developing Stat3 antagonists may effectively impair tumor angiogenesis.
Results

Activation of IL-6R induces HIF-1a expression
VEGF upregulation in cancer cells is induced by a large number of receptor and nonreceptor oncoproteins (Rak et al., 1995; Dankbar et al., 2000; Laughner et al., 2001; Karni et al., 2002; Niu et al., 2002b; Wei et al., 2003b; Tan et al., 2004) . While many of these oncogenic growth-signaling molecules have been shown to induce HIF-1a protein synthesis (Semenza, 2003) , whether IL-6 could upregulate HIF-1a expression has not yet been reported. As IL-6R overactivation has been observed in a number of human cancers (Hideshima et al., 2004) , we addressed whether IL-6R engagement activates HIF-1a. HIF-1a protein levels in MCF-7 human breast tumor cells were induced by IL-6 in a dose-dependent manner ( Figure 1a) .
It has been well documented that while hypoxiainduced HIF-1a expression is regulated at the protein stability level, HIF-1a expression induced by oncogenic growth signaling is regulated at the protein synthesis level (Laughner et al., 2001; Karni et al., 2002; Semenza, 2003) . An earlier report has also shown that HIF-1a expression is controlled at the RNA level in For the total Akt protein detection, the antibody is specific for Akt1. IL-6 treatment also increases Stat3 DNA-binding activity, and expression of VEGF Targeting Stat3 blocks both HIF-1 and VEGF Q Xu et al rodent cells (Jiang et al., 1997) . We therefore determined how IL-6R activation might regulate HIF-1a expression. Northern blot analysis indicates that HIF-1a induction is not regulated at the mRNA level in MCF-7 breast cancer cells exposed to IL-6 (Figure 1b ). Blocking protein synthesis by cycloheximide (CHX) abrogated the increase in HIF-1a level induced by IL-6 ( Figure 1c ). As the half-life of HIF-1a is only approximately 5 min, the disappearance of HIF-1a protein in the presence of CHX for 15 min or longer suggest that IL-6 signaling affects HIF-1a expression at the protein synthesis level, consistent with the previously reported mechanism for growth signaling-induced HIF1a regulation (Laughner et al., 2001; Karni et al., 2002) . It has been also demonstrated that PI3K/Akt pathway is required for growth signaling-induced HIF-1a upregulation (Laughner et al., 2001; Karni et al., 2002) . The ability of IL-6 to activate PI3K/Akt signaling has been reported (Hideshima et al., 2001) . Activation of IL-6R in MCF-7 cells increased Akt activity as shown by phosphorylation of AKT, and to a lesser degree, the total protein level of AKT1 (Figure 1d ). In addition to PI3K/Akt, the ability of IL-6 signaling to activate Jak/Stat3 pathway has been documented (Catlett-Falcone et al., 1999) . Activation of IL-6R in MCF-7 cells, which have little endogenous constitutive Stat3 activity, stimulated Stat3 DNA-binding ( Figure 1d ). Activation of Akt and Stat3 by IL-6 was accompanied by an induction of both HIF-1a and VEGF (Figure 1c and d) .
Stat3 is obligatory for IL-6-induced HIF-1a and VEGF expression A previous study showed that in cervical cancer cells with constitutively-activated IL-6R, blocking Stat3 caused inhibition of VEGF expression (Wei et al., 2003b) . In contrast, targeting PI3K, which is upstream Akt and thereby is expected to inhibit HIF-1a expression, did not interfere with VEGF expression (Wei et al., 2003b) . To investigate whether Stat3 has a regulatory role in HIF-1a expression, we first determined HIF-1a induction by IL-6R signaling in tumor cells stably expressing siRNA/Stat3. MCF-7 tumor cells were transfected with either a control plasmid vector (pSilencer 1.0-U6) or the same vector encoding siRNA/ Stat3. The effect of the siRNA inhibition of Stat3 in the tumor cells surviving G418 antibiotics selection was confirmed by Western blot analysis and by EMSA ( Figure 2a , bottom panels). Furthermore, while control cells exhibit detectable HIF-1a expression, little HIF-1a protein was detected in MCF-7 cells stably transfected with siRNA/Stat3 with and without IL-6 stimulation ( Figure 2a) . Moreover, whereas a significant induction of VEGF by IL-6 stimulation was observed in control MCF-7 cells, no VEGF expression was detectable in IL-6-treated MCF-7 cells expressing siRNA/Stat3 (Figure 2a ). These data suggest that Stat3 is necessary for both basal and IL-6-induced upregulation of HIF-1a and VEGF.
Stat3 is required for HIF-1a and VEGF induction by activated Src and Her-2/Neu
Like IL-6R signaling, Src tyrosine kinase is known to activate both Jak/Stat3 and PI3K/Akt pathways (Yu et al., 1995; Liu et al., 1998 demonstrated that Src tyrosine kinase activity-induced VEGF expression requires Stat3 in mouse 3T3 fibroblasts (Niu et al., 2002b) , while other studies have shown that Src activity induces the protein synthesis of HIF-1a (Karni et al., 2002) . The question remains whether Stat3 is also required for HIF-1a upregulation induced by Src activity. Our published data demonstrated that blocking Stat3 in v-Src3T3 cells inhibits VEGF expression (Niu et al., 2002b) . Data in Figure 2b show that transforming 3T3 cells with v-Src leads to an increase in HIF-1a protein level, whereas blocking Stat3 signaling in v-Src/3T3 cells with Stat3D, a dominantnegative Stat3 mutant, abrogates v-Src-induced HIF-1a expression ( Figure 2b ). We further tested whether blocking Stat3 would inhibit Src-induced HIF-1a expression in human A2056 melanoma cells, which exhibit activated endogenous c-Src and is responsible for Stat3 activation (Niu et al., 2002a) . Interrupting Stat3 signaling in A2058 tumor cells by siRNA/Stat3 also reduced HIF-1a protein expression (Figure 2c ). Moreover, VEGF expression and Stat3 DNA-binding activity in A2058 melanoma cells were downregulated in the presence of siRNA/Stat3 (Figure 2c ). These data demonstrate that blocking Stat3 signaling inhibits expression of both HIF-1a and VEGF induced by cSrc activity known to activate both Stat3 and PI3/Akt pathways. In addition to Src tyrosine kinase, activation of Her-2/Neu has also been shown to induce HIF-1a expression through the PI3K/Akt pathway (Laughner et al., 2001) . As shown in Figure 3a , heregulin induces HIF-1a expression in MCF-7 cells. While MCF-7 breast cancer cells displayed little endogenous activated Stat3, stimulation with heregulin at 100 ng/ml led to detectable levels of activated Stat3 (Figure 3a ). This upregulation of Stat3 corresponded to an increase in HIF-1a expression in control but not siRNA/Stat3 MCF-7 breast cancer cells (Figure 3b ). Moreover, Her-2 activation by heregulin upregulates VEGF expression in control but not Stat3/siRNA MCF-7 tumor cells, suggesting a critical requirement for Stat3 in Her-2-induced HIF-1a and VEGF expression. Like Her-2, EGFR engagement/ overactivity is known to activate Stat3 signaling . Our results using Stat3 antisense oligonucleotide indicate that Stat3 is also required for both HIF-1a and VEGF upregulation by EGF stimulation in DU145 human prostate cancer cells (data not shown).
Stat3 regulates Akt gene expression
Our data thus far demonstrate that Stat3 is required for HIF-1a induction by various growth signaling molecules. The question remains as to how Stat3 might regulate HIF-1a expression. Several reports have shown that HIF-1a induction by Her2/neu and Src is mediated by the PI3K/Akt signaling pathway (Jiang et al., 2001; Laughner et al., 2001; Karni et al., 2002; Semenza, 2003) . While the ability of Her2/neu to activate Akt has been demonstrated (Wen et al., 2000; Zhou et al., 2001) , whether Stat3 is involved in regulating Akt1 expression or activity remains to be explored. IL-6 signalinginduced total Akt1 protein level was less in Stat3 knockdown MCF-7 breast cancer cells than control MCF-7 cells (Figure 4a, left) . To eliminate the possibility that tumor cells might have unique mutations that nonspecifically influence these findings, we performed the same experiments using primary mouse embryonic fibroblasts (MEFs) with or without the Stat3 alleles (Figure 4a, right) .
We next investigated whether Stat3 might regulate Akt gene expression. Transcriptional regulation of the Akt1 gene by Stat3 was investigated by cloning a 2.2 kb Akt1 promoter DNA fragment, beginning 2.2 kb upstream from the ATG translation start site, into the luciferase reporter vector, pGL3. Cotransfecting the pGL3/Akt1 promoter construct with an expression plasmid encoding a constitutively activated Stat3 mutant, Stat3C, into NIH 3T3 cells resulted in upregulation of Akt1 promoter activity (Figure 4b) . The 2.2 kb Akt1 promoter region contains 13 consensus STAT DNA-binding sequences, TT(N) 4À6 AA. We identified Stat3 binding to the Akt1 promoter region by chromatin immunoprecipitation (ChIP) assays, followed by PCR using two pairs of Akt1 promoter specific primers. For the ChIP assays, expression vectors encoding v-Src and wild-type Stat3 were transfected into HEK293 cells. Results from ChIP assays indicate that Stat3 protein binds to both fragments of the 2.2 kb Akt1 promoter region (Figure 4c ). This together with Western blot analyses data demonstrate that Stat3 participates in regulating Akt1 expression, suggesting that Stat3 increases HIF-1a levels through Akt1.
Effects of small-molecule Stat3 inhibitors on HIF-1a and VEGF expression
To date, several Stat3-selective small molecule inhibitors -phosphopeptide (Turkson et al., 2001 ) and peptidomimetics (Turkson et al., 2004) Targeting Stat3 inhibits tumor angiogenesis induced by both Jak/STAT and PI3K/Akt pathways Our data thus far identify Stat3 as an effective target for blocking VEGF expression induced by several major activators of VEGF. We next determined whether blocking Stat3 would result in inhibition of tumor angiogenesis in vivo. A2058 human melanoma tumors, which display activated Stat3 due to activation of endogenous c-Src, were allowed to reach approximately 5 mm in diameter before mice were treated with the Stat3 inhibitor, CPA-7. Although in vivo Stat3 inhibition by CPA-7 in tumors lasted only one day, treating mice with CPA-7 twice a week (i.v.) significantly inhibited tumor growth (Figure 6a ). To assess whether antiangiogenesis effects might contribute to CPA-7-induced tumor growth inhibition, we harvested three tumors from mice treated with both vehicle and CPA-7 on day 8 to compare their vascular density. Since tumor volumes of CPA-7-treated mice were smaller than control mice, which might potentially influence tumor vessel density and therefore complicate interpretation of data, we included an additional control group that was given vehicle treatment when tumor volumes were considerably smaller. Thus, several vehicle-treated tumors of comparable sizes to CPA-7-treated tumors were obtained for measuring microvessel density. Microvessel density was significantly reduced in tumors from CPA-7-treated mice when compared to vehicle-treated groups (no difference was detected between the two vehicletreated groups) (Figure 6b ). Data from the above experiments indicate that targeting Stat3 inhibits tumor growth involving antiangiogenesis effect. Since blocking Stat3 is known to induce tumor cell death and/or growth inhibition, we used an independent system, which does not involve this hypothesis, control and siRNA/Stat3 MCF-7 tumor cells were serum-starved for 4 h, followed by IL-6 stimulation to activate both Jak/STAT and PI3K/Akt pathways. The MCF-7 tumor cells were then mixed with Matrigel and implanted in vivo. Angiogenesis was considerably reduced in the Matrigel containing siRNA/Stat3 MCF-7 tumor cells compared to that of control MCF-7 cells (Figure 6c ). Moreover, when stimulated by IL-6, the control MCF-7 tumor cells were able to induce substantially more angiogenesis than their siRNA/Stat3 counterpart (Figure 6c ). These results demonstrate that blocking Stat3 in tumor cells abrogates tumor angiogenesis induced by activation of both PI3K/Akt and Jak/Stat3 pathways.
Discussion
Our data demonstrate that Stat3 is a key regulator of VEGF induced by multiple oncogenic growth signaling Yu and Jove, 2004) . The ability of Stat3 to activate the VEGF gene as a direct transcriptional activator has previously been demonstrated (Niu et al., 2002b; Wei et al., 2003a) . The data presented here show that Stat3 is also required for growth signalinginduced expression of HIF-1, the only other known inducible transcription factor of the VEGF promoter. A requirement of Akt1 signaling for growth signal-induced HIF-1a protein synthesis has been previously established (Semenza, 2003) . Our results also identify Akt1 as a target gene of Stat3. Moreover, our data show that blocking Stat3 signaling inhibits tumor growth, reduces angiogenesis and abrogates tumor angiogenesis induced by simultaneous activation of Jak/Stat3 and PI3K/Akt signaling pathways. However, whether Stat3 contributes to HIF-1 expression/activity independent of Akt remains to be determined. Our data substantiate how targeting a single transcription factor potentially neutralizes the oncogenic potential of a multitude of upstream genetic aberrations (Darnell, 2002; Yu and Jove, 2004) . As proposed by Darnell, transcription factors pose ideal targets for cancer therapy because a large array of diverse oncogenic/angiogenic proteins feed into a relatively small number of signaling pathways (Darnell, 2002) . Oncogenic signaling pathways in turn converge upon a limited set of nuclear transcription factors, the final 'switches' determining gene expression patterns and ultimately leading to malignancy (Darnell, 2002) . Recent work by Gray et al. (2005) also demonstrates that binding of both Stat3 and HIF to the VEGF promoter is required for optimal VEGF expression under hypoxia. Together with our findings, these results add a new dimension to the importance of targeting key transcription factors for cancer therapy.
Although direct inhibition of specific transcription factors with small molecules has been perceived to be a major challenge, Stat3 peptide inhibitors based upon rational design have been obtained (Turkson et al., 2001) . Moreover, combinatorial chemical libraries are being used to systematically convert these short peptides to peptidomimetics. The phosphopeptide sequence, PY*LKTK, and its peptidomimetic derivatives disrupt Stat3 dimerization with biological implications (Turkson et al., 2004) . In addition to structure-based rational approaches, the availability of constructs in which luciferase expression is under the control of a Stat3-dependent responsive element allows cell-based, highthroughput screens of random chemical libraries for identifying specific inhibitors of Stat3. Our results here demonstrate that Stat3 inhibitors identified from such screens (Turkson et al., 2004) also block the expression of HIF-1a and VEGF. Furthermore, inhibiting Stat3 by CPA-7 in vivo can inhibit tumor growth and tumor angiogenesis. The success of generating the first lead compounds inhibiting Stat3 activity and angiogenesis raises the possibility that targeting Stat3 with potent small-molecule drugs, actively being developed and/or modified, may provide an exciting novel approach for clinical antiangiogenesis therapy.
This work demonstrates that Stat3 is required for both HIF-1 and VEGF expression induced by oncoproteins commonly activated in cancer. Stat3 also regulates angiogenesis at another critical level: Stat3 signaling is necessary for endothelial cell proliferation, migration and microvascular tube formation (Deo et al., 2002; Bartoli et al., 2003; Yahata et al., 2003) . It has been demonstrated that VEGFR signals through Stat3 in endothelial cells (Bartoli et al., 2003) . Blocking Stat3 in endothelial cells has been demonstrated to completely inhibit their migration and vessel formation (Yahata et al., 2003) . Moreover, Stat3 in endothelial cells is obligatory for the signaling of bFGF receptor (Deo et al., 2002) . Our present study provides proof-ofconcept that targeting Stat3 effectively blocks production of VEGF and tumor angiogenesis. Based upon these findings, Stat3 emerges as a molecular target whose inhibition not only prevents tumor cell production of angiogenic factor(s) but also endothelial cells' response to these factors. Interestingly, a similar relationship between tumor Stat3 activity and dendritic cell Stat3 signaling has been recently described (Wang et al., 2004) . These studies show that Stat3 activity promotes the production of tumor factors, including VEGF, that activate Stat3 signaling in dendritic cells, leading to inhibition of dendritic cell maturation. Conversely, blocking Stat3 signaling in either tumor or dendritic cells abrogates tumor-induced inhibition of dendritic cell maturation (Wang et al., 2004) . Thus, Stat3 plays a central role in propagating oncogenic signals from tumor cells to effector cells involved in tumor angiogenesis and immune evasion. It has been well established that blocking Stat3 signaling in tumor cells with constitutively activated Stat3 inhibits tumor cell proliferation and induces apoptosis (Darnell, 2002; Yu and Jove, 2004) . In diverse human cancers displaying dependence on persistently activated Stat3 for survival/proliferation (Darnell, 2002; Yu and Jove, 2004) , targeting Stat3 is expected to evoke potent antitumor effects through direct tumor cell death, antitumor immune responses and antiangiogenesis.
Materials and methods
The following reagents were purchased from various companies as indicated: IL-6 (BD Pharmingen); cycloheximide (Calbiochem); G418 (Cellgro); anti-VEGF monoclonal antibody (R&D); anti-HIF-1a polyclonal antibody and anti-bactin monoclonal antibody (Santa Cruz Biotechnology); anti-HIF-1b monoclonal antibody (NOVUS Biologicals); antiPhospho-Akt (Cell Signaling).
Generation of Stat3 knockdown tumor cell lines and Stat3 knockout mouse embryonic fibroblasts (MEFs)
MCF-7 breast cancer cells, DU145 prostate cancer cells and A2058 melanoma cells were cultured in high-glucose RPMI 1640 supplemented with 10% FBS and penicillin-streptomycin. The Stat3siRNA oligonucleotide, AATTAAAAAAGTC AGGTTGCTGGTCAAATTCTCTTGAAATTTGACCAGC AACCTGACTTCC, was inserted into pSilencer 1.0-U6 (Takeda et al., 1997) , but the MEFs were transduced with a control empty retroviral vector.
Western blot analysis
MCF-7 cells and MEFs were serum starved for 20 h in serumfree medium before exposure to IL-6 for 6 h. 50 mg of nuclear or whole-cell extracts was used for Western blot analysis. HIF-1a rabbit polyclonal antibody (H-206) (1 : 500 dilution), HIF-1b mouse monoclonal antibody (1 : 1500 dilution), Akt1 mouse monoclonal, anti-phospho-Akt rabbit polyclonal and anti-VEGF monoclonal antibody (1 : 1000 dilutions) were used for the Western blot analyses. Horseradish peroxidaseconjugated sheep anti-mouse and donkey anti-rabbit or antigoat secondary antibodies were used at 1 : 2000 and 1 : 5000 dilutions, respectively. The signal was developed with SuperSignal West Pico Chemiluminescent Substrate (PIERCE).
Electrophoretic mobility shift assay (EMSA)
Stat3 DNA-binding assays were performed as described previously (Catlett-Falcone et al., 1999) .
Northern blot analysis
TRIzol reagent (Invitrogen) was used to isolate total RNAs, which were fractionated by 1% agarose-formaldehyde gel electrophoresis, followed by transferring onto nylon membranes and hybridization with 32 P-labeled human HIF-1a cDNA.
Pulse-label assays
Pulse-label assays were performed according to previously described methods (Laughner et al., 2001) . Briefly, MCF-7 tumor cells (2 Â 10 6 ) were plated in a 10-cm dish, starved for 20 h and treated with 20 ng/ml IL-6 for 30 min in methionine-free DMEM. Before harvesting cells, [ 35 S]Met-Cys was added to final concentration of 0.3 mCi/ml and pulse-labeled for 20-40 min. Preparation of extracts and immunoprecipitation with HIF-1a antibody was carried out as described (Laughner et al., 2001) .
Cloning and analysis of human Akt1 promoter
To clone the Akt1 promoter, a DNA fragment containing Akt1 genomic sequences upstream of the translational start site was obtained by screening a human placenta genomic library (Stratagene) with a 5 0 cDNA fragment of the Akt1. We used the following primers for subcloning of Akt1 promoter region: (5 0 ) upstream region 5 0 -GGCTAGCCACAAAGGACTGT GACC-3 0 ; (3 0 ) downstream region 5 0 -GCTTCCTTT GCTT CTCCCAGAGG-3 0 . PCR amplified 2.2-kb Akt1 promoter fragment was subcloned into the pGL3 vector at BglII-HindIII sites (Promega). The construct was confirmed by DNA sequencing. Reporter assays were performed using the luciferase assay system according to the manufacture's procedure (Promega).
Chromatin immunoprecipitation (ChIP) assays
Soluble chromatin was prepared from a total of 2 Â 10 7 HEK293 cells that were transiently transfected with v-Src and wt-Stat3 expression vectors. Immunoprecipitation was performed with either an anti-STAT3 antibody or an unrelated antibody (Akt1 antibody). Following extensive washing, the immunoprecipitates were crosslinked and treated with proteinase K and RNase A. Purified DNA was subjected to PCR. The sequences of the PCR primers used are as follows: region 1 forward ( þ ): 5 0 -GGATAAAGTGTGCTCAGGT GAGGG-3 0 , reverse (À) : ATTCTAGGCTTAGAGCCTCCA GCC-3 0 ; region 2 forward ( þ ) : 5 0 -ACTCAGCAAGCTCT CAGGCTCTGG-3 0 , reverse (À) : 5 0 -CATTTACTGAACACC CACTTGCG-3 0 . The two fragments from the PCR reactions cover the 2.2 kb Akt1 promoter. PCR products were resolved on an agarose gel and visualized by BioImage.
In vivo tumor experiments and matrigel assays
Athymic (nu/nu) 6-week-old male mice (NCI) were maintained under pathogen-free conditions in accordance with established institutional guidance and approved protocols. 2 Â 10 6 A2058 cells were injected to induce tumors. After tumors reached 3-5 mm in diameter, mice were injected (i.v.) with either vehicle (10% DMSO/PBS) or 5 mg/kg CPA-7 twice weekly. Matrigel assays were performed as described previously (Niu et al., 2002b) . Briefly, 2 Â 10 6 MCF-7 tumor cells stably transfected with either an empty control vector or Stat3siRNA expression vector were suspended in 100 ml PBS and mixed with 0.5 ml Matrigel (Collaborative Biochemical Products) on ice, followed by subcutaneous injection into the abdominal midline of nude nice. On day 5, Matrigel plugs were harvested for photography and hemoglobin content assays. Hemoglobin quantification was carried out by the Drabkin method. Briefly, after dissecting away all the surrounding tissue, Matrigel pellets were melted at 41C and assayed for hemoglobin content (Drabkin's reagent kit, Sigma).
Angiogenesis measurements
Angiogenesis quantification was performed in a doubleblinded fashion by the staff at the Analytic Microscopy Core of Moffitt Cancer Center and Research Institute. SPOT Advanced imaging software (v. 3.4.5) was used to capture bright-field images from two fields for each sample. Data for these image files were collected using the Count/Size function of Image-Pro Plus software (v. 5.0). The blood vessels (CD31-positive areas) were selected using the histogram and dropper tools. The Count function was then used to total the number of regions (CD31-positive areas). Measurement was selected within the Count/Size function and the Area tool was utilized to calculate the area of CD31-positive blood vessels in each entire field. Every field in each of the entire tumor section was examined and included in the analysis.
